Remove Communication Remove Immunity Remove Vaccines
article thumbnail

Temperature-stable tuberculosis vaccine induces immune response

European Pharmaceutical Review

The first clinical trial of any subunit tuberculosis (TB) vaccine in a temperature-stable form has found that ID93+GLA-SE, a freeze-dried vaccine, was safe. The recombinant subunit vaccine is made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant.

Immunity 103
article thumbnail

Advancing research on human immune systems in India to develop better vaccines

Express Pharma

The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Reductionist systems, such as genetically identical inbred mice, have long been the choice for immunology research, which focuses on studying the cells, tissues, and organs that make up the immune system.

Immunity 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Herd immunity is nice – but what about me?

pharmaphorum

Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. While these numbers do tell us something about the relative immunity of the population writ large, they don’t tell us anything about our own, personal immune profiles. However, we’ve also found a number of outliers.

Immunity 105
article thumbnail

IIL develops needle-free intranasal COVID-19 booster vaccine

Express Pharma

Indian Immunologicals Limited (IIL) has announced the development of a live-attenuated, needle-free intranasal booster vaccine against SARS-CoV-2. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over.

Vaccines 104
article thumbnail

After a Vaccine – What? The Shift from Research and Discovery to Communications

Eye on FDA

Vaccines for COVID-19 are the focus of the moment – politically and scientifically speaking. Scientifically, there was the big news that a vaccine trial had experienced a serious adverse event bringing a pause to bear in its continuation, likely throwing further cold water on the political side of the equation.

article thumbnail

Large UK study suggests vaccination helps treat long COVID

pharmaphorum

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 124
article thumbnail

As the Prospect of a Vaccine Approaches, Business and Communications Challenges Are Just Around the Corner

Eye on FDA

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.